BioSpace News Archive

Yellowstone Biosciences, a pioneer of soluble bispecific T-cell receptor -based therapies for human leukocyte antigen Class II targets in oncology, launches to unlock a new class of therapeutically targetable, frequently expressed antigens with potential to significantly transform patient lives.

MediciNova, Inc. announces that its Chief Business Officer, David H. Crean, Ph.D., will assume management of the Company’s investor engagement, corporate communications, and public relations activities.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes.

Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines known as AIMs, announced that Nature Medicine has published groundbreaking exploratory data from the Company’s Phase 1 clinical trial of UB-312 in patients with Parkinson’s disease.

Ocugen, Inc. announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced preclinical data from two separate research collaborations.

Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, presented progress across two of its preclinical programs, including first-time demonstration in NHPs of efficient in vivo rewriting at the SERPINA1 locus responsible for AATD.

Aldeyra Therapeutics, Inc. today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today.

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date.

BPGbio, Inc. today announced its sponsorship and participation in the United Mitochondrial Disease Foundation ’s Mitochondrial Medicine Conference taking place June 26-29, 2024 in Cleveland, Ohio.